Vol. 2, Issue 8, Part L (2016)

Materials and Methods: This randomized, two-arm comparative study was conducted over one year, involving 30 patients (15 in each group). Baseline and post-treatment assessments included spirometry, six-minute walk test, Borg Dyspnea Score, and sputum analysis for inflammatory markers (MPO and IL-8). Plasma theophylline levels were monitored in the combination group.

Results: Combination therapy significantly reduced sputum MPO levels (4.60±0.09 to 1.97±0.09 IU/g, p = 0.0018) compared to monotherapy (3.25±1.01 to 1.97±0.06 IU/g, p>0.05). Both groups showed modest, non-significant improvements in FEV1 and six-minute walk distance. IL-8 levels and other inflammatory markers showed minor changes without statistical significance.

Conclusion: The combination of fluticasone and Deriphyllin® offers superior anti-inflammatory effects compared to monotherapy, highlighting its potential in managing inflammation-driven COPD. However, its impact on lung function and exercise tolerance remains comparable, necessitating further investigation.